Results from a real-world study (NCT06462014) describing the use of relugolix in patients with prostate cancer within the VHA were posted on ClinicalTrials.gov on 2025-12-11. The study included 507 participants and focused on their demographics and clinical characteristics.
Background
The study aimed to describe the demographics and clinical characteristics of patients with prostate cancer who initiated treatment with relugolix within the Veterans Health Administration (VHA) system.
Trial design
This real-world observational study (NCT06462014) was completed and enrolled 507 participants with prostate cancer. The study's objective was to learn about the demographics and clinical characteristics of these patients who initiated relugolix.
Key results
The study collected data on participant characteristics and treatment history. Key measurements included:
- Regarding geographic region, participant counts were 240, 94, 93, and 80 across different regions.
- For the index year, participant counts were 0, 81, 203, and 223 across different years.
- The mean time from the first observed prostate cancer diagnosis date to the index date was 55.8 months (Standard Deviation: 61.7 months).
- For previous treatments received, participant counts were 103, 86, and 77 for different types of treatments.
What this means
This real-world study provides a descriptive overview of patients with prostate cancer who received relugolix within the VHA. The data on geographic distribution, index year, time from diagnosis, and previous treatments offers insights into the characteristics of this patient population in a clinical practice setting. This information can help clinicians and researchers understand the real-world utilization patterns and patient profiles associated with relugolix treatment for prostate cancer.
Source
The information for these trial results was sourced from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT06462014, titled "Description of Relugolix Use in Patients With Prostate Cancer Within the VHA," were posted on 2025-12-11 on clinicaltrials.gov.